Liquid biopsy: Will it be the 'magic tool' for monitoring response of solid tumors to anticancer therapies?

Current Opinion in Oncology

Volumn 27, Issue 6, 2015, Pages 560-567

  Gingras, Isabelle ^a   Salgado, Roberto ^a   Ignatiadis, Michail ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Biomarkers; Cancer; Circulating tumor cells; Circulating tumor DNA; Liquid biopsy

Indexed keywords

BIOLOGICAL MARKER; CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE MARKER; DNA DETERMINATION; GENE FREQUENCY; GENE MUTATION; GENOMICS; HUMAN; LIQUID BIOPSY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; TUMOR BIOPSY; BIOPSY; BLOOD; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSPECTIVE STUDY; TUMOR EMBOLISM;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BIOPSY; CLINICAL TRIALS AS TOPIC; DNA, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84944056882     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000223     Document Type: Review

References (105)

1. Ignatiadis M, Dawson S-J. Circulating Tumor Cells and Circulating tumor DNA for precision medicine: dream or reality? Ann Oncol 2014; 25:2304-2313.
2. Krebs MG, Metcalf RL, Carter L, et al. Molecular analysis of circulating tumour cells: biology and biomarkers. Nat Rev Clin Oncol 2014; 11:129-144.
3. Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat Rev Cancer 2014; 14:623-631.
4. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199-1209.
5. Murtaza M, Dawson SJ, Tsui DW, et al. Noninvasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497:108-112.
6. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4:136ra168.
7. Leary RJ, Sausen M, Kinde I, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 2012; 4:162ra154.
8. Rothe F, Laes JF, Lambrechts D, et al. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 2014; 25:1959-1965.
9. Paoletti C, Li Y, Muniz MC, et al. Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase II trial: TBCRC 019. Clin Cancer Res 2015; 21:2771-2779.
10. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32:3483-3489.
11. Bidard F-C, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014; 15:406-414.
12. Rack B, Schindlbeck C, Juckstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106. [Epub ahead of print]. doi: 10.1093/jnci/dju066.
13. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12:4218-4224.
14. Sastre J, Vidaurreta M, Gomez A, et al. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. Clin Colorectal Cancer 2013; 12:280-286.
15. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:3213-3221.
16. Huang X, Gao P, Song Y, et al. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer 2014; 14: Article ID 976.
17. van Dalum G, Stam GJ, Scholten LF, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol 2015; 46:1361-1368.
18. Romiti A, Raffa S, Di Rocco R, et al. Circulating tumor cells count predicts survival in colorectal cancer patients. J Gastrointestin Liver Dis 2014; 23:279-284.
19. Sotelo MJ, Sastre J, Maestro ML, et al. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer. Ann Oncol 2015; 26:535-541.
20. Lee SJ, Lee J, Kim ST, et al. Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int J Biol Markers 2015; [Epub ahead of print]. doi: 10.5301/jbm.5000151.
21. Okabe H, Tsunoda S, Hosogi H, et al. Circulating tumor cells as an independent predictor of survival in advanced gastric cancer. Ann Surg Oncol 2015. [Epub ahead of print]. doi 10.1245/s10434-015-4483-6.
22. Reeh M, Effenberger KE, Koenig AM, et al. Circulating tumor cells as a biomarker for preoperative prognostic staging in patients with esophageal cancer. Ann Surg 2015; 261:1124-1130.
23. Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer 2013; 119:3984-3991.
24. Bidard FC, Huguet F, Louvet C, et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol 2013; 24:2057-2061.
25. Han L, Chen W, Zhao Q. Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Tumour Biol 2014; 35:2473-2480.
26. Ma XL, Li YY, Zhang J, et al. Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev 2014; 15:6015-6020.
27. Tjensvoll K, Nordgard O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer 2014; 134:1-8.
28. Huang CH, Wick JA, Sittampalam GS, et al. A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker in patients with extensive small-cell lung cancer. Front Oncol 2014; 4: Article ID 271.
29. Igawa S, Gohda K, Fukui T, et al. Circulating tumor cells as a prognostic factor in patients with small cell lung cancer. Oncol Lett 2014; 7:1469-1473.
30. Fu L, Liu F, Fu H, et al. Circulating tumor cells correlate with recurrence in stage III small-cell lung cancer after systemic chemoradiotherapy and prophylactic cranial irradiation. Jpn J Clin Oncol 2014; 44:948-955.
31. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with nonsmall-cell lung cancer. J Clin Oncol 2011; 29:1556-1563.
32. Wang J, Wang K, Xu J, et al. Prognostic significance of circulating tumor cells in nonsmall-cell lung cancer patients: a meta-analysis. PLoS One 2013; 8:e78070.
33. Goldkorn A, Ely B, Quinn DI, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 2014; 32:1136-1142.
34. Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33:1348-1355.
35. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14:6302-6309.
36. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28:3107-3114.
37. Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer. Gynecol Oncol 2011; 122:567-572.
38. Zeng L, Liang X, Liu Q, et al. The predictive value of circulating tumor cells in ovarian cancer: a meta analysis. Int J Gynecol Cancer 2015. [Epub ahead of print]
39. Wang Z, Cui K, Xue Y, et al. Prognostic value of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Med Oncol 2015; 32: Article ID 164.
40. Mockelmann N, Laban S, Pantel K, et al. Circulating tumor cells in head and neck cancer: clinical impact in diagnosis and follow-up. Eur Arch Otorhinolaryngol 2014; 271:15-21.
41. Hoshimoto S, Faries MB, Morton DL, et al. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 2012; 255:357-362.
42. Khoja L, Lorigan P, Dive C, et al. Circulating tumor cells as tumor biomarkers in melanoma: detection methods and clinical relevance. Ann Oncol 2014.
43. Ignatiadis M, Riethdorf S, Bidard FC, et al. International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res 2014; 16:R43.
44. Paoletti C, Muniz MC, Thomas DG, et al. Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor positive breast cancer. Clin Cancer Res 2015; 21:2487-2498.
45. Aceto N, Bardia A, Miyamoto DT, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158:1110-1122.
46. Adams DL, Martin SS, Alpaugh RK, et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci 2014; 111:3514-3519.
47. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371:1028-1038.
48. Deng G, Krishnakumar S, Powell AA, et al. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer 2014; 14: Article ID 456.
49. Fernandez SV, Bingham C, Fittipaldi P, et al. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res 2014; 16: Article ID 445.
50. Markou A, Farkona S, Schiza C, et al. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res 2014; 20:5823-5834.
51. Polzer B, Medoro G, Pasch S, et al. Molecular profiling of single circulating tumor cells with diagnostic intention. EMBO Mol Med 2014; 6:1371-1386.
52. Pestrin M, Salvianti F, Galardi F, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol 2015; 9:749-757.
53. Lyberopoulou A, Aravantinos G, Efstathopoulos EP, et al. Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue. PLoS One 2015; 10:e0123902.
54. Mohamed Suhaimi NA, Foong YM, Lee DY, et al. Noninvasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients. Mol Oncol 2015; 9:850-860.
55. Kuhlmann JD, Wimberger P, Bankfalvi A, et al. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem 2014; 60:1282-1289.
56. Pailler E, Auger N, Lindsay CR, et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged nonsmall-cell lung cancer. Ann Oncol 2015; 26:1408-1415.
57. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014; 32:479-484.
58. Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345:216-220.
59. Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 2015; 75:892-901.
60. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20:897-903.
61. Karabacak NM, Spuhler PS, Fachin F, et al. Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 2014; 9:694-710.
62. Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014; 512:155-160.
63. Onstenk W, Sieuwerts AM, Weekhout M, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett 2015; 362:36-44.
64. Mouliere F, Robert B, Arnau Peyrotte E, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011; 6:e23418.
65. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med 2014; 6:224ra224.
66. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20:548-554.
67. Hamakawa T, Kukita Y, Kurokawa Y, et al. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer 2015; 112:352-356.
68. Kidess E, Heirich K, Wiggin M, et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, highsensitivity multiplexed mutation detection platform. Oncotarget 2015; 6:2549-2561.
69. Reinert T, Scholer LV, Thomsen R, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2015. [Epub ahead of print]. doi: 10.1136/gutjnl-2014-308859.
70. Turner NC, Garcia-Murillas I, Schiavon G, et al. Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. J Clin Oncol 2014; 32 (suppl; abstr 511) Available at: http://meetinglibrary.asco.org/content/134201-144.
71. Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med 2015. doi: 10.15252/emmm.201404913.
72. Madic J, Kiialainen A, Bidard FC, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer 2015; 136:2158-2165.
73. Singh N, Gupta S, Pandey RM, et al. High levels of cell-free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival. Cancer Invest 2015; 33:78-85.
74. Spindler K-LG, Appelt AL, Pallisgaard N, et al. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. Int J Cancer 2014; 135:2984-2991.
75. Wong AL, Lim JS, Sinha A, et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 2015; 13: Article ID 57.
76. Martignetti JA, Camacho-Vanegas O, Priedigkeit N, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA. Neoplasia 2014; 16:97-103.
77. Tie J, Kinde I, Wang Y, et al. Circulating Tumor DNA as an Early Marker of Therapeutic Response in Patients with Metastatic Colorectal Cancer. Ann Oncol 2015; 26:1715-1722.
78. Sefrioui D, Perdrix A, Sarafan-Vasseur N, et al. Short report:Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer 2015. doi: 10.1002/ijc.29612.
79. Guttery DS, Page K, Hills A, et al. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer. Clin Chem 2015; 61:974-982.
80. Oshiro C, Kagara N, Naoi Y, et al. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat 2015; 150:299-307.
81. Beaver JA, Jelovac D, Balukrishna S, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014; 20:2643-2650.
82. Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med 2014; 20:430-435.
83. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21:795-801.
84. Morelli MP, Overman MJ, Dasari A, et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 2015; 26:731-736.
85. Braig F, Marz M, Schieferdecker A, et al. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. Oncotarget 2015; 6:12035-12047.
86. Balgkouranidou I, Matthaios D, Karayiannakis A, et al. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients. Mutation Res 2015; 778:46-51.
87. Shoda K, Masuda K, Ichikawa D, et al. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. Gastric Cancer 2014; doi 10.1007/s10120-014-0432-5.
88. Kinugasa H, Nouso K, Miyahara K, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer 2015; 121:2271-2280.
89. Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015; 21:3196-1203.
90. Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2015; 24:206-212.
91. Piotrowska Z, Niederst MJ, Karlovich CA, et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790Mpositive cancers with a third-generation EGFR inhibitor. Cancer Discov 2015; 5:713-722.
92. Mazurek A, Pierzyna M, Giglok M, et al. Quantification of concentration and assessment of EGFR mutation in circulating DNA. Cancer Biomark 2015.
93. Douillard JY, Ostoros G, Cobo M, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9:1345-1353.
94. Mahon KL, Qu W, Devaney J, et al. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer 2014; 111:1802-1809.
95. Chang-Hao Tsao S, Weiss J, Hudson C, et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci Rep 2015; 5: Article ID 11198.
96. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al. Quantitative cellfree circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem 2015; 61:297-304.
97. Barault L, Amatu A, Bleeker FE, et al. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol 2015. doi: 10.1093/annonc/mdv272.
98. Kang G, Bae BN, Sohn BS, et al. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor. Target Oncol 2015. doi: 10.1007/s11523-015-0361-1.
99. Combaret V, Iacono I, Bellini A, et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med 2015; 4:540-550.
100. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and metaanalysis. Sci Rep 2014; 4: Article ID 6269.
101. Li Z, Zhang Y, Bao W, et al. Insufficiency of peripheral blood as a substitute tissue for detecting EGFR mutations in lung cancer: a meta-analysis. Target Oncol 2014; 9:381-388.
102. Karachaliou N, Mayo-de las Casas C, Queralt C, et al. ASsociation of egfr l858r mutation in circulating free dna with survival in the eurtac trial. J Am Med Assoc Oncol 2015; 1:149-157.
103. Spindler KL, Pallisgaard N, Andersen RF, et al. Changes in mutational status during third-line treatment for metastatic colorectal cancer-results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma. Int J Cancer 2014; 135:2215-2222.
104. Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a noninvasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. Mol Oncol 2015; 9:783-790.
105. De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol 2014; 25:1729-1735.